Menarini Silicon Biosystems Transforms Metastatic Breast Cancer Treatment
In a breakthrough analysis from the PACE trial, Menarini Silicon Biosystems has underscored the significant role of Circulating Tumor Cells (CTCs) in guiding treatment for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer. This analysis reveals how counting CTCs in the bloodstream provides critical information, allowing healthcare professionals to make informed decisions regarding treatment adjustments, whether to escalate or de-escalate therapies for enhanced patient outcomes.
Understanding the PACE Trial
The PACE trial, a multicenter phase II clinical study, officially launched in 2017, analyzed the prognostic implications of CTC counts in breast cancer patients who showed progression after first-line therapies that included aromatase inhibitors and CDK4/6 inhibitors. A total of 203 patients were involved in the study. Participants received either endocrine monotherapy, a combination of endocrine therapy with a CDK4/6 inhibitor, or a triplet regimen incorporating an immune checkpoint inhibitor.
Categorizing Patients Based on CTC Count
According to CTC levels, patients were classified into two distinct prognostic groups. Those with fewer than 5 CTCs per 7.5 mL of blood were considered to have indolent disease, while those with 5 CTCs or more were classified as having aggressive disease. Although no notable difference in progression-free survival was observed across treatment groups in the general patient population, the sub-group with aggressive disease exhibited substantial improvements in outcomes with combination therapies. Patients with aggressive disease experienced a stunning 57% reduction in progression risk when treated with doublet therapy and a remarkable 74% reduction with triplet therapy compared to monotherapy.
Your Health Matters: Insights from Renowned Professionals
Dr. Lorenzo Gerratana, an esteemed Associate Professor and Physician Scientist at IRCCS CRO Aviano in Italy, emphasized the importance of CTC enumeration in personalizing treatment. He stated, "This analysis highlights how identifying HR+/HER2- metastatic breast cancer patients through their CTC counts can lead to better-targeted therapies following progression after first-line treatment. Patients experiencing aggressive disease significantly benefitted from intensified treatment plans, while those with indolent disease saw minimal benefits." This revelation reinforces the necessity of reliable biomarkers in the ongoing battle against evolving cancer treatments.
Comparative Insights from the STIC Trial
Recent findings from the PACE trial resonate with earlier results from the STIC trial, published in 2024. This earlier research suggested that treatment strategies informed by CTC counts differed from traditional physician choices. When these strategies were in conflict, the outcomes often resulted in either improved survival rates or allowed for safe treatment de-escalation without adversely affecting patient longevity.
Menarini's Commitment to Revolutionizing Cancer Care
Fabio Piazzalunga, President of Menarini Silicon Biosystems, expressed optimism about these findings. He stated, "The STIC and PACE trials consistently show how our CELLSEARCH CTC enumeration can enhance patient management in the complex realm of metastatic breast cancer. Here, chronic challenges, such as disease progression and resistance mechanisms, need innovative solutions." He added, "Our technology is currently available for In Vitro Diagnostic Use in Europe and China, and patients in the U.S. can access it through our accredited laboratory in Huntingdon Valley, Pa. We remain dedicated to equipping physicians with the necessary tools to adjust treatment plans effectively, whether to combat disease progression aggressively or to preserve patient quality of life through thoughtful treatment reductions."
About CELLSEARCH
CELLSEARCH represents the only CE-marked, clinically validated blood test cleared by the FDA for counting CTCs. This test aids physicians in managing patients afflicted with metastatic forms of breast, prostate, and colorectal cancers. It is crucial to note that the CELLSEARCH CTC Kit is designed for investigational use beyond its approved indications, highlighting the need for ongoing research and regulatory review.
Corporate Overview of Menarini Silicon Biosystems
Menarini Silicon Biosystems operates out of Bologna, Italy, and Huntingdon Valley, Pa., as a wholly owned subsidiary of the Menarini Group. The larger Menarini Group stands as a formidable player in the pharmaceutical, biotechnology, and diagnostics sectors, boasting over 17,000 dedicated employees across 140 countries.
Frequently Asked Questions
What was the primary objective of the PACE trial analysis?
The PACE trial aimed to investigate the utility of CTC enumeration in guiding treatment for patients with HR+/HER2- metastatic breast cancer.
How does CTC enumeration influence treatment decisions?
CTC counts help stratify patients into different prognostic groups, guiding healthcare providers in determining whether to escalate or de-escalate treatment strategies based on disease aggressiveness.
What were the key findings for aggressive disease patients in the study?
Patients with aggressive disease experienced significant reductions in progression risk with combination therapies, showing a 57% risk reduction with doublet therapy and a 74% reduction with triplet therapy compared to monotherapy.
How does the CELLSEARCH test fit into the current treatment landscape?
CELLSEARCH is instrumental in managing patients by providing reliable CTC counts, which can improve treatment outcomes in metastatic cancer settings.
Where is the CELLSEARCH technology available?
The test is available for In Vitro Diagnostic Use in Europe and China, and patients in the U.S. can access it through accredited laboratories.
